Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2026 16:30 ET | Source: Evaxion

Evaxion to present new data at AACR Annual Meeting

Two abstracts accepted for presentationOne abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01Another abstract on the use of Evaxion’s AI-Immunology™...
February 18, 2026 11:03 ET | Source: Research and Markets

Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Cancer Vaccines - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into over...
November 07, 2025 17:10 ET | Source: Evaxion

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the...
November 03, 2025 09:00 ET | Source: Evaxion

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate...
October 17, 2025 08:15 ET | Source: Evaxion

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation...
October 13, 2025 08:00 ET | Source: Evaxion

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing...
May 22, 2025 08:00 ET | Source: Evaxion Biotech

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data packageWill provide insights...
April 28, 2025 08:00 ET | Source: Evaxion Biotech

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the...
March 25, 2025 16:30 ET | Source: Evaxion Biotech

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the...
March 25, 2025 09:56 ET | Source: Research and Markets

Personalized Cancer Vaccine Market & Clinical Trials Outlook 2025: BioNTech, Moderna and myNEO Therapeutics Lead Race in Personalized Cancer Vaccines

Dublin, March 25, 2025 (GLOBE NEWSWIRE) -- The "Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering. ...